Revenue Warning

As X4 Pharmaceuticals preps for a key investor summit, all eyes are on its pivotal trial for chronic neutropenia and the commercial fate of XOLREMDI®.

Risen Energy's new solar module ranks in the global top three for efficiency, but the company's dual strategy extends its ambitions from Earth to orbit.

Anterix hires a new product chief and sees its COO depart, signaling a major pivot from spectrum provider to a full-service solutions leader for utilities.